No attachments available.
TECHNOLOGY LICENSING OPPORTUNITY: Clathrate Therapeutics Platform
Contact and place of performance
Caleb Ledgerwood
Los Alamos, NM 87545
USA
This technology from scientists at Los Alamos National Laboratory represents a novel platform for improving the safety and effectiveness of therapeutic gas-based treatments by enabling controlled, localized delivery at the site of disease. By addressing longstanding challenges associated with systemic exposure and dosing precision, the platform enhances the clinical viability of gas therapies across high-value market...
View moreHow it Works:
The Clathrate Therapeutics Platform uses a proprietary, controlled-release system designed to localize therapeutic gases at the intended treatment site rather than allowing them to disperse systemically. This technology temporarily stabilizes the gas within a biocompatible structure that gradually releases it under physiological conditions, enabling sustained and targeted exposure. This controlled release approach is designed to support therapeutic concentrations where needed while limiting circulating levels elsewhere in the body. An integrated computational modeling capability further supports optimization of dosing profiles and treatment parameters, helping guide development decisions prior to in vivo studies.
Key Advantages:
Market Applications:
Development Status: TRL 2
US patent pending
LA-UR-26-22810
LANL Tech Partnerships: Unlock the Innovative Potential
Los Alamos National Laboratory offers a wide range of cutting-edge technologies and capabilities that may provide your company with a competitive edge in the market and unlock the innovative potential that can enhance, refine, and revolutionize your products.
LANL’s licensing program focuses on moving inventions developed by our researchers to commercial innovations. Patented and patent pending inventions and copyrighted software are available to existing and start-up companies through exclusive and non-exclusive licensing agreements. For specific discussions, please contact [email protected].
Note: This is not a call for external services for the development of this technology.
https://www.lanl.gov/engage/collaboration/feynman-center/partner-with-us/licensing-technology
m.lanl.gov/tech-search
The U.S. Department of Energy, through Triad - DOE Contractor at Los Alamos National Laboratory, is issuing special notice S-195396 regarding a technology licensing opportunity for the Clathrate Therapeutics Platform. This opportunity is classified under NAICS 325412 Pharmaceutical Preparation Manufacturing and PSC 6505 Drugs and Biologicals, with no set-aside (NONE; NONE). The platform represents a novel system designed to improve the safety and effectiveness of therapeutic gas-based treatments by enabling controlled, localized delivery at the site of disease. By stabilizing gas within a biocompatible structure, the technology enables sustained exposure under physiological conditions while limiting systemic exposure and reducing toxicity risks.
The scope of this technology includes applications across oncology, cardiovascular care, neuroprotection, and regenerative medicine. The platform features an integrated computational modeling capability to support treatment optimization and reduce technical risk during development. Currently at Technology Readiness Level (TRL) 2 with a pending U.S. patent (LA-UR-26-22810), the architecture is designed for integration with drug-device combinations and existing treatment modalities. This licensing program aims to move the invention from the laboratory to commercial innovation through exclusive or non-exclusive agreements.
Performance is based in Los Alamos, New Mexico, and the response deadline for this notice is December 4, 2026. Caleb Ledgerwood is the designated point of contact for this opportunity. There are zero attachments associated with this notice, which serves as a solicitation for licensing interest rather than a call for external development services.
Generated by Lumen AI
Scoped analysis and attachments—go beyond the summary when you need detail from the solicitation package.